Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and %3e 10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124:511–8.
Druker BJ, O'Brien SG, Jorge C, Jerald R. Chronic myelogenous leukemia. Curr Opin Oncol. 2001;13:3.
Ruibao R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172–83.
Moraes GND, Souza PS, Costas FCDF, Vasconcelos FC, Maia RC. The Interface between BCR-ABL-dependent and -independent resistance signaling pathways in chronic myeloid leukemia. Leukemia Res Treatment. 2012;2012:671702.
Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. J Cell Physiol. 2019;234:12369–84.
Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615–27.
Zhou J, Xie M, Shi Y, et al. MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells. Oncol Rep. 2015;34:111.
Cui Z, Luo Z, Lin Z, et al. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis. J Gene Med. 2019;21:e3083.
Luan W, Shi Y, Zhou Z, et al. circRNA_0084043 promote malignant melanoma progression via miR-153-3p/Snail axis. Biochem Biophys Res Commun. 2018;502:22–9.
Jiang J, Liu Y, Zhao Y, Tian F, Wang G. miR-153-3p suppresses inhibitor of growth protein 2 expression to function as tumor suppressor in acute lymphoblastic leukemia. Technol Cancer Res Treatment. 2019;18:1533033819852990.
Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science. 2004;306:990–5.
Ankit K, Umesh Kumar S, Anurag C. Targeting autophagy to overcome drug resistance in cancer therapy. Future Med Chem. 2015;7:1535–42.
Takahashi Y, Coppola D, Matsushita N, et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol. 2007;9:1142–51.
Zhu J, Li Y, Huang C, Huang H. Abstract 3310: Atg7 overexpression promotes bladder cancer invasion via autophagic removal of AUF1 protein and subsequently increased RhoGDI2 mRNA stability in vitro and in vivo. Can Res. 2017;77:3310–410.
Rohatgi RA, Shaw LM. An autophagy-independent function for Beclin 1 in cancer. Mol Cell Oncol. 2016;3(1):e1030539.
Alexander Scarth W, Monika M, Anna KS. Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. Cell Cycle. 2011;10:1719–25.
Crowley LC, Elzinga BM, O'Sullivan GC, Mckenna SL. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment. Am J Hematol. 2011;86:38–47.
Cristian B, Maria Rosa L, Ashley H, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Investig. 2009;119:1109–23.
Beth L, Sangita S, Guido K. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy. 2008;4:600–6.
Manabu E, Ryungsa K, Kazuaki T, et al. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res. 2005;7:R940–R952952.
Lin TY, Chen KC, Liu HJ, et al. MicroRNA-1301-mediated RanGAP1 downregulation induces BCR-ABL nuclear entrapment to enhance imatinib efficacy in chronic myeloid leukemia cells. PLoS ONE. 2016;11:e0156260.
Flis S, Chojnacki T. Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities. Drug Des Devel Ther. 2019;13:825–43.
Zhu X, Lin Z, Du J, et al. MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia. Sci Rep. 2015;5:12460.
Tanida I, Ueno T, Kominami E. LC3 and autophagy. Methods Mol Biol. 2008;445:77–88.
Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leukemia. 2013;13:515–29.
Lu Y, Liu LL, Liu SS, et al. Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells. J Transl Med. 2016;14:270.
Testa U, Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica. 2007;92:81.
Colin J, Gaumer S, Guenal I, Mignotte B. Mitochondria, Bcl-2 family proteins and apoptosomes: of worms, flies and men. Front Biosci. 2008;14:4127–37.
Chiang W-C, Wei Y, Kuo Y-C, et al. High-throughput screens to identify autophagy inducers that function by disrupting Beclin
1/Bcl-2 binding. ACS Chem Biol. 2018;13:2247–60
Sun D, Mu Y, Piao H. MicroRNA-153-3p enhances cell radiosensitivity by targeting BCL2 in human glioma. Biol Res. 2018;51:56.